Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach
Dengue fever is one of the significant fatal mosquito-borne viral diseases and is considered to be a worldwide problem. <i>Aedes</i> mosquito is responsible for transmitting various serotypes of dengue viruses to humans. Dengue incidence has developed prominently throughout the world in...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-11-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/11/1940 |
| _version_ | 1827643584130580480 |
|---|---|
| author | Md. Zeyaullah Khursheed Muzammil Abdullah M. AlShahrani Nida Khan Irfan Ahmad Md. Shane Alam Razi Ahmad Wajihul H. Khan |
| author_facet | Md. Zeyaullah Khursheed Muzammil Abdullah M. AlShahrani Nida Khan Irfan Ahmad Md. Shane Alam Razi Ahmad Wajihul H. Khan |
| author_sort | Md. Zeyaullah |
| collection | DOAJ |
| description | Dengue fever is one of the significant fatal mosquito-borne viral diseases and is considered to be a worldwide problem. <i>Aedes</i> mosquito is responsible for transmitting various serotypes of dengue viruses to humans. Dengue incidence has developed prominently throughout the world in the last ten years. The exact number of dengue cases is underestimated, whereas plenty of cases are misdiagnosed as alternative febrile sicknesses. There is an estimation that about 390 million dengue cases occur annually. Dengue fever encompasses a wide range of clinical presentations, usually with undefinable clinical progression and outcome. The diagnosis of dengue depends on serology tests, molecular diagnostic methods, and antigen detection tests. The therapeutic approach relies completely on supplemental drugs, which is far from the real approach. Vaccines for dengue disease are in various stages of development. The commercial formulation Dengvaxia (CYD-TDV) is accessible and developed by Sanofi Pasteur. The vaccine candidate Dengvaxia was inefficient in liberating a stabilized immune reaction toward different serotypes (1–4) of dengue fever. Numerous promising vaccine candidates are now being developed in preclinical and clinical stages even though different serotypes of DENV exist that worsen the situation for a vaccine to be equally effective for all serotypes. Thus, the development of an efficient dengue fever vaccine candidate requires time. Effective dengue fever management can be a multidisciplinary challenge, involving international cooperation from diverse perspectives and expertise to resolve this global concern. |
| first_indexed | 2024-03-09T17:56:17Z |
| format | Article |
| id | doaj.art-81a3211b97f34fb78cbe1fc413ec509f |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T17:56:17Z |
| publishDate | 2022-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-81a3211b97f34fb78cbe1fc413ec509f2023-11-24T10:16:58ZengMDPI AGVaccines2076-393X2022-11-011011194010.3390/vaccines10111940Preparedness for the Dengue Epidemic: Vaccine as a Viable ApproachMd. Zeyaullah0Khursheed Muzammil1Abdullah M. AlShahrani2Nida Khan3Irfan Ahmad4Md. Shane Alam5Razi Ahmad6Wajihul H. Khan7Department of Basic Medical Science, College of Applied Medical Sciences, Khamis Mushayt Campus, King Khalid University (KKU), Abha 62561, Saudi ArabiaDepartment of Public Health, College of Applied Medical Sciences, Khamis Mushayt Campus, King Khalid University (KKU), Abha 62561, Saudi ArabiaDepartment of Basic Medical Science, College of Applied Medical Sciences, Khamis Mushayt Campus, King Khalid University (KKU), Abha 62561, Saudi ArabiaDepartment of Chemical Engineering, Indian Institute of Technology Delhi, New Delhi 110016, IndiaDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University (KKU), Abha 62561, Saudi ArabiaDepartment of Medical Laboratory Technology, College of Applied Medical Sciences, Jazan University, Jazan 45142, Saudi ArabiaDepartment of Chemistry, Indian Institute of Technology Delhi, Hauz Khas, New Delhi 110016, IndiaDepartment of Microbiology, All India Institute of Medical Sciences Delhi, New Delhi 110029, IndiaDengue fever is one of the significant fatal mosquito-borne viral diseases and is considered to be a worldwide problem. <i>Aedes</i> mosquito is responsible for transmitting various serotypes of dengue viruses to humans. Dengue incidence has developed prominently throughout the world in the last ten years. The exact number of dengue cases is underestimated, whereas plenty of cases are misdiagnosed as alternative febrile sicknesses. There is an estimation that about 390 million dengue cases occur annually. Dengue fever encompasses a wide range of clinical presentations, usually with undefinable clinical progression and outcome. The diagnosis of dengue depends on serology tests, molecular diagnostic methods, and antigen detection tests. The therapeutic approach relies completely on supplemental drugs, which is far from the real approach. Vaccines for dengue disease are in various stages of development. The commercial formulation Dengvaxia (CYD-TDV) is accessible and developed by Sanofi Pasteur. The vaccine candidate Dengvaxia was inefficient in liberating a stabilized immune reaction toward different serotypes (1–4) of dengue fever. Numerous promising vaccine candidates are now being developed in preclinical and clinical stages even though different serotypes of DENV exist that worsen the situation for a vaccine to be equally effective for all serotypes. Thus, the development of an efficient dengue fever vaccine candidate requires time. Effective dengue fever management can be a multidisciplinary challenge, involving international cooperation from diverse perspectives and expertise to resolve this global concern.https://www.mdpi.com/2076-393X/10/11/1940dengue<i>Aedes</i> mosquitoclinical presentationsdiagnosisdengue vaccines |
| spellingShingle | Md. Zeyaullah Khursheed Muzammil Abdullah M. AlShahrani Nida Khan Irfan Ahmad Md. Shane Alam Razi Ahmad Wajihul H. Khan Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach Vaccines dengue <i>Aedes</i> mosquito clinical presentations diagnosis dengue vaccines |
| title | Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach |
| title_full | Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach |
| title_fullStr | Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach |
| title_full_unstemmed | Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach |
| title_short | Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach |
| title_sort | preparedness for the dengue epidemic vaccine as a viable approach |
| topic | dengue <i>Aedes</i> mosquito clinical presentations diagnosis dengue vaccines |
| url | https://www.mdpi.com/2076-393X/10/11/1940 |
| work_keys_str_mv | AT mdzeyaullah preparednessforthedengueepidemicvaccineasaviableapproach AT khursheedmuzammil preparednessforthedengueepidemicvaccineasaviableapproach AT abdullahmalshahrani preparednessforthedengueepidemicvaccineasaviableapproach AT nidakhan preparednessforthedengueepidemicvaccineasaviableapproach AT irfanahmad preparednessforthedengueepidemicvaccineasaviableapproach AT mdshanealam preparednessforthedengueepidemicvaccineasaviableapproach AT raziahmad preparednessforthedengueepidemicvaccineasaviableapproach AT wajihulhkhan preparednessforthedengueepidemicvaccineasaviableapproach |